Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | CCR5 | P51681 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7509409 | 0.84 | CCR1 (0.58) | CCR1RAB9ACCR5CYP1A2GAA | |
| SCHEMBL69979 | 0.84 | CRHBP (0.37) | KMT2A | |
| SCHEMBL12446258 | 0.76 | CCR1 (0.71) | CCR1RAB9ACCR5CYP1A2KMT2A | |
| SCHEMBL2901701 | 0.76 | NOS2 (0.50) | CCR1RAB9ACCR5CYP1A2ADORA1 | |
| SCHEMBL29414112 | 0.76 | NOS2 (0.50) | CCR1RAB9ACCR5CYP1A2ADORA1 | |
| SCHEMBL31153402 | 0.73 | CYP1A2 (0.46) | CCR1RAB9ACCR5CYP1A2KDM4E | |
| SCHEMBL20671158 | 0.73 | CYP1A2 (0.46) | CCR1RAB9ACCR5CYP1A2KDM4E | |
| SCHEMBL6412343 | 0.73 | PIK3CD (0.40) | RAB9AKMT2AKDM4EALDH1A1 | |
| SCHEMBL22337665 | 0.71 | CRHBP (0.30) | — | |
| SCHEMBL19001477 | 0.71 | CCR1 (0.44) | CCR1RAB9ACCR5CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024074611-A1 | PRMT5 INHIBITORS | Ryvu Therapeutics S.A. (PL) | 2024-04-11 | — | — | WO | disclosed |
| EP-3252045-B1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2867221-B1 | CYANOGUANIDINES AND THEIR SUE AS ANTIVIRAL AGENTS. | ABBVIE INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-3252045-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | AbbVie Inc. (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | ABBVIE INC. | 2015-11-12 | — | — | US | disclosed |
| WO-2014005129-A1 | CYANOGUANIDINES AND THEIR USE AS ANTIVIRAL AGENTS | ABBVIE INC. (US) | 2014-01-03 | — | — | WO | disclosed |
| EP-0446604-A2 | Pyridine and related aza heterocycle derivatives as cardiovascular agents | AMERICAN CYANAMID COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322045-A1 | CYANOGUANIDINES AND USES THEREOF | GMPS, RNGTT, RNMT | CCR1 677/4885RAB9A 384/4885CCR5 882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.